Published May 16, 2022
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses daratumumab (Darzalex), 1,800 mg/15 mL (120 mg/mL) for subcutaneous injection.
- Indication: In combination with bortezomib, cyclophosphamide, and dexamethasone, for the treatment of adult patients with newly diagnosed light chain amyloidosis.